Key result
Higher BNP predicts ~0.2% greater risk of adverse outcomes per pg/ml in ICD patients.
Why the study?
Do BNP levels predict event-free survival (malignant tachyarrhythmias, death, or heart transplantation) in heart failure patients with ICDs?
Cohort (n=123)
Do BNP levels predict event-free survival (malignant tachyarrhythmias, death, or heart transplantation) in heart failure patients with ICDs?
Relative Risk: 1.002 (95% CI 1.001–1.003)
p-value: p=<0.001
BNP plasma levels are a useful prognostic marker for predicting event-free survival, including malignant tachyarrhythmias, in heart failure patients with ICDs, outperforming LV ejection fraction.
No takes yet. Share an insight, caveat, or question.
May aid risk stratification in HF-ICD patients; hypothesis-generating and should not yet change practice without prospective validation.
Christ et al. (2006) conducted a cohort in chronic heart failure with implantable cardioverter defibrillators (n=123). B-type natriuretic peptide (BNP) levels was evaluated on combined endpoint of malignant tachyarrhythmias, death or heart transplantation (RR 1.002 per pg/ml increment, 95% CI 1.001-1.003, p=<0.001). Higher B-type natriuretic peptide levels predicted adverse outcomes (tachyarrhythmias, death, or transplant) in ICD patients (RR 1.002 per pg/ml increment; 95% CI 1.001-1.003; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: